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Abstract 
Background: The Republic of Congo adopted a new anti‑malarial treatment policy in 2006, with artesunate‑amodi‑
aquine (ASAQ) and artemether‑lumefantrine (AL) as the first‑ and second‑line anti‑malarial drugs, respectively. Only 
three clinical studies had been conducted before the policy change. A randomized study on these two artemisinin‑
based combinations was conducted, and the effect that sickle cell trait may have on treatment outcomes was evalu‑
ated in children under 10 years old followed during 12 months in Brazzaville in 2010–2011.
Methods: A cohort of 330 children under 10 years of age living in a suburban area in the south of Brazzaville were 
passively followed for registration of malaria episodes. Uncomplicated Plasmodium falciparum episodes were ran‑
domly treated with co‑formulated ASAQ (Coarsucam®) or AL (Coartem®). Patients were followed according to the 
2009 World Health Organization protocol for the evaluation of anti‑malarial drug efficacy. Plasmodium falciparum 
recrudescent isolates were compared to pre‑treatment isolates by polymerase chain reaction (PCR) to distinguish 
between re‑infection and recrudescence. PCR‑uncorrected and PCR‑corrected responses to treatment were deter‑
mined using per protocol analysis. Haemoglobin type (AA, AS, SS) was determined by PCR.
Results: Of 282 clinical malaria episodes registered during 1‑year follow‑up period, 262 children with uncomplicated 
malaria were treated with ASAQ (129 patients) or AL (133 patients). The PCR‑corrected efficacy, expressed as the 
percentage of adequate clinical and parasitological response, was 97.0 % for ASAQ and 96.4 % for AL. Among ASAQ‑
treated patients, 112 (86.8 %) carried AA genotype and 17 (13.2 %) were AS carriers. The PCR‑corrected efficacy was 
96.4 % for AA‑carriers and 100 % for AS‑carriers treated with ASAQ [relative risk (RR) = 0.96; 95 % confidence interval, 
0.93–1.00, p = 0.5]. Among 133 AL‑treated children, 109 (82 %) carried AA, and 24 (18 %) AS genotypes. The PCR‑cor‑
rected efficacy was 96.7 % among AA‑carriers and 95.2 % among AS‑carriers [RR = 1.01 (0.92–1.12), p = 0.6]. Nausea, 
jaundice, headache, dizziness, vomiting, pruritus, abdominal pain, and diarrhoea were registered as adverse events in 
both groups. ASAQ was associated with significantly more frequent adverse events (P < 0.05).
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Background
In the 1990s, with the emergence and spread of chloro-
quine resistance, malaria accounted for 37  % of hospi-
talizations and represented the first cause of admissions 
to paediatric service of the main hospital in Brazzaville, 
Republic of Congo (RoC) [1]. A significant increase in 
the cases of cerebral malaria leading to death was also 
observed [2]. In health facilities situated in urban areas, 
15–30 % of febrile patients had been found to be carriers 
of malaria parasites, while in suburban areas, 40–50 % of 
patients were infected [3].
4-aminoquinolines and quinoline-like derivatives (chlo-
roquine, amodiaquine) and sulfadoxine-pyrimethamine 
(SP) have lost their efficacy for the treatment of uncom-
plicated falciparum malaria in RoC [4, 5]. Indeed, almost 
all of Plasmodium falciparum isolates analysed in earlier 
studies carried the key pfcrt K76T mutation associated 
with chloroquine resistance, while quadruple mutations 
[defined as dihydrofolate reductase (dhfr) mutant alleles 
Asn51Ile + Cys59Arg + Ser108Asn and dihydropteroate 
syntase (dhps) mutant allele Ala437Gly] were present in 
more than 50  % of the isolates obtained from patients 
with SP treatment failure [6, 7]. Under these conditions, 
the management of malaria in health centres and at home 
had become difficult with anti-malarial drugs available in 
the early 2000s [8].
Artemisinin derivatives (artesunate, artemether, dihy-
droartemisinin) in combination with amodiaquine, 
sulfadoxine-pyrimethamine, lumefantrine, mefloquine, 
piperaquine, or pyronaridine have largely replaced chlo-
roquine and sulfadoxine-pyrimethamine as effective 
alternative drugs. In the early 2000s, the World Health 
Organization (WHO) strongly recommended a change 
of malaria treatment policies based on artemisinin-based 
combination therapy (ACT) [9, 10]. By 2006, 36 African 
countries had changed their policies, but only 18 imple-
mented their new policies [11], while in 2011, ACT was 
available in all African countries [12]. The progressive 
introduction of ACT and vector control measures have 
significantly reduced the prevalence of clinical cases and 
mortality due to malaria [13, 14].
In 2006, RoC adopted a new treatment policy for 
uncomplicated malaria with artesunate-amodiaquine 
(ASAQ) and artemether-lumefantrine (AL) as the first- 
and second-line drugs, respectively [15]. Three clini-
cal studies were conducted before the decision: one 
randomized study in a rural area near Brazzaville [16] 
and two non-randomized studies in Brazzaville [17, 18]. 
In these three published studies, non-co-formulated 
drugs were administered to symptomatic patients. Due 
to the limited data on the clinical efficacy of ACT, fur-
ther clinical studies are required to cover the rest of the 
country to monitor the efficacy of ASAQ and AL using 
co-formulated drugs.
It has been observed that anti-malarial treatment 
failures may be caused by many factors other than the 
intrinsic susceptibility of P. falciparum to the anti-malar-
ial drug being tested [19]. Therefore, an understanding of 
the different factors that influence the clinical and para-
sitological response is important for the correct inter-
pretation of estimates of drug efficacy. There are several 
studies suggesting that host genetic factors play a role in 
determining anti-malarial treatment outcome, including 
evidence for an increased effect of sulfadoxine-pyrimeth-
amine against P. falciparum in the presence of the sickle 
cell trait (HbAS) or a reduced efficacy of chloroquine and 
artemisinin derivatives in patients with α-thalassaemia 
[20–23].
This is the first randomized trial conducted in Braz-
zaville between 2010 and 2011 in which the efficacy of 
co-formulated ASAQ and AL and the implication of the 
sickle cell trait on treatment outcomes were evaluated.
Methods
Study site and population
The study was performed from April 2010 to March 2011 
in Madibou and Mbouono, two suburban areas located 
in Makélékélé, one of the seven districts of Brazzaville. 
According to the data obtained from the General Census 
of Population in 2007, there were 1,373,382 inhabitants 
in Brazzaville, and Makélékélé, one of its seven districts, 
had 298,292 inhabitants. Makélékélé is largely covered 
by vegetation and crossed by several streams that pro-
vide sources of water for agricultural activities (Fig. 1). In 
this study area, Ngoko, Kinsana, and Mayala are part of 
Madibou; Ntietie, Malanda Yabi, Collinaud, and Nkoutou 
are part of Mbouono. A public health facility is located in 
Madibou which refers some patients to the district hos-
pital in Makélékélé, located in the centre of the district. 
In the 1980s, malaria transmission had been described as 
intense and perennial, with an entomological inoculation 
rate of 200–1000 infective bites/person/year [24]. Since 
Conclusion: This first randomized study in Brazzaville confirmed the excellent efficacy of these co‑formulated anti‑
malarial drugs in children. Sickle cell genotype did not influence the treatment efficacy of artemisinin‑based combi‑
nation therapy.
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Fig. 1 Maps of the study zone. 1 Republic of Congo; 2 map of Brazzaville and the location of study zone; 3 details of study zone (local subdivisions)
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then, there has been no update with more recent ento-
mological studies.
The study population was a cohort of 330 children 
under 10 years, established after a population census. Of 
17,636 inhabitants in the study area, 3058 (17.3 %) were 
children under 10 years of age.
Patients
Children were examined and passively followed for febrile 
illnesses at the parents’ request by a medical doctor in the 
medical unit established at the Makélékélé district hospi-
tal, located about 6 km from the study area. Fingerprick 
capillary blood was obtained to prepare Giemsa-stained 
smears for malaria parasite examination by microscopy. 
After obtaining informed consent from one of the par-
ents, venous blood sample was collected from children 
with positive smears for P. falciparum malaria parasites 
in ethylene diaminetetraacetic acid (EDTA)-coated tubes 
to determine haematological parameters using Beckman 
Coulter ACT Diff (Beckman Coulter; Brea, CA, USA).
Febrile children with positive smears were randomized to 
receive ASAQ or AL if the following conditions were met: 
monoinfection with P. falciparum, parasitaemia ≥1000 
asexual parasites per microlitre of blood, absence of severe 
malnutrition, danger signs (i.e., inability to stand, breast-
feed, or drink, recent convulsions, lethargy, or persistent 
vomiting), signs of severe and complicated malaria, and any 
febrile conditions due to diseases other than malaria [25].
Treatment
In the present randomized, open-label study, patients 
were assigned to one of the treatment groups using a 
computer-generated table of random numbers pre-
pared in advance by a statistician. Drugs were adminis-
tered for three consecutive days (day 0, 1, and 2). ASAQ 
(Coarsucam®, Sanofi-Aventis, Antony, France) treat-
ment group received standard once-daily doses based 
on body weight. ASAQ was administered with water. 
AL (Coartem®, Novartis Pharma, Basel, Switzerland) 
was administered with milk, two doses/day, for 3  days. 
All ASAQ doses were administered under the supervi-
sion of a nurse. Only the first, third, and fifth doses of AL 
were supervised during daily consultation. The second, 
fourth, and sixth doses of AL were given to parents for 
administration at home at a specified time. A supply of 
powdered milk was provided to the parent or guardian 
for drug administration. As the medical unit conducting 
the present study was far from the residential area, the 
phone number of parents was recorded to remind them 
to administer the second dose eight hours after the first 
dose, as well as before the fourth and sixth doses.
After drug administration, the patient was observed 
for 30  min to record any vomiting which required 
re-treatment. A second vomiting resulted in the exclu-
sion of children from the drug evaluation protocol and 
administration of artesunate by intramuscular route. 
Three doses of paracetamol were provided to the parents 
for fever management at home.
Follow‑up
Patients were followed on an outpatient basis on days 1, 
2, 3, 7, 14, 21 and 28 according to the 2009 WHO pro-
tocol [25]. If the patients were absent on the appoint-
ment day, the study team visited their homes. From day 
2 to day 28, two thick films were made for the systematic 
control of parasitaemia. However, in case of high fever or 
danger signs on day 1, thick smears were prepared and 
examined immediately. From day 14, fingerprick capil-
lary blood was collected on Whatman 3MM filter papers, 
dried for 24 h at 37 °C, sealed in plastic bags, and stored 
in a dry place.
Fever with negative smears was routinely treated with 
paracetamol and amoxycilline when an antibiotic was 
needed. If an antibiotic with anti-malarial activity was 
prescribed by the medical staff, the child was excluded 
from the assessment of anti-malarial drug efficacy, but 
was still followed, as part of the cohort.
If recrudescent malaria parasites were diagnosed, chil-
dren initially treated with ASAQ at inclusion received AL 
as the second-line treatment, while those who were ini-
tially treated with AL at inclusion received ASAQ. These 
children were followed for additional 28 days.
Drug safety and tolerability
From day 1 to day 28, adverse events were assessed indi-
rectly by questioning the parents or actively by clini-
cal exploration to detect any symptoms or signs that 
were absent on day 0. An adverse event was defined as 
a sign, symptom, or illness, which was absent on day 0 
but occurred during follow-up. All adverse events were 
recorded in individual case record file.
Malaria diagnosis and haematological and biochemical 
analyses
Giemsa-stained thick films were examined under the 
microscope. Asexual parasites were counted against 200 
white blood cells (WBCs) and expressed as the number 
of asexual parasites/μL of blood, assuming a WBC count 
of 8000/μL of blood. In case of hyperparasitaemia, the 
parasite count was determined when 500 asexual para-
sites were counted even if 200 WBCs were not reached. 
Parasite density was determined by two independent 
technicians. Additional thick films were prepared from 
venous blood and stained 24 h later. The results of both 
blood examinations were compared and expressed as the 
mean of two results.
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Malaria parasite genotyping
DNA was extracted from Whatman 3MM filter papers by 
the Chelex method [26]. As recommended by the WHO 
[27], pre-treatment and post-treatment isolates were 
compared sequentially by nested PCR using merozoite 
surface protein-2 (msp2), merozoite surface protein-1 
(msp1), and glutamine-rich protein (glurp) polymor-
phic genetic markers. Primary PCR was performed to 
amplify fragments of the markers with primers hybrid-
izing within conserved regions. Secondary nested PCR 
was performed with internal primers specific to allelic 
families: 3D7 and FC27 for msp2 and K1, MAD20, and 
RO33 for msp1. PCR products were visualized by fluo-
rescent end-labelling of internal primers. After capil-
lary electrophoretic separation with automated DNA 
sequencer ABI310 (Applied Biosystems), allele size and 
peak heights for individual alleles were measured using 
GeneScan software (Applied Biosystems). Minor peaks 
<25  % of the amplitude of the predominant allele and 
poorly amplified loci with <200 fluorescence units were 
discarded. Recrudescence was defined as the presence 
of at least one identical size allele in all three markers (or 
the presence of some, or all, identical size alleles in case 
of multiple alleles). Reinfection was defined as the pres-
ence of different size allele (or the presence of all alleles 
of different sizes, in case of multiple alleles) in one of the 
three markers.
Haemoglobin genotyping
Genomic human DNA was extracted from 200  μL of 
whole blood sample using Qiaamp DNA blood mini kit 
(Qiagen, Hilden, Germany) according to the manufactur-
er’s instruction. DNA was recovered in 200 μL of elution 
buffer provided in the kit and stored at −20 °C until use.
The polymorphism in the β-chain of the globin gene at 
codon six was determined by using an allele-specific PCR 
method [28, 29]. The PCR conditions were as follows: one 
cycle of 5 min at 94 °C, 25 cycles of 94 °C for 1 min, 55 °C 
for 2  min, and 72  °C for 3  min. As quality control, two 
PCR amplifications were performed for each sample for 
A and S gene detection. The expected fragment length 
was 203  bp. DNA samples extracted from individuals 
with known AA, AS and SS haemoglobin were used as 
controls. PCR products were analysed by electrophoresis 
in a 1.5 % agarose gel.
Treatment outcomes
The primary end-points were PCR-unadjusted and PCR-
adjusted cure rates on day 28. Clinical outcome was clas-
sified as early treatment failure (ETF), late clinical failure 
(LCF), late parasitological failure (LPF), adequate clinical 
and parasitological response (ACPR), and proportion of 
new infections after PCR analysis of blood samples from 
patients with recurrent parasitaemia. The second end-
points were proportions of treated patients with fever 
and parasitaemia on day 2 and day 3, and adverse events 
from day 1 to day 7.
Statistical analyses
The number of recruited patients with uncomplicated 
malaria from the cohort was based on the assumption of 
0.8–0.9 uncomplicated malaria episode/child/year, which 
would allow recruitment of 260–300 malaria-infected 
children randomly assigned to one of the two treatment 
arms, ASAQ and AL, in a year. Per-protocol (PP) data 
were analysed using a pre-programmed Excel 7 spread-
sheet provided by the Department of Global Malaria 
Programme, WHO (Geneva, Switzerland). This analysis 
method allows a direct comparison of data of the present 
study with those of previous studies [17, 18].
The Chi square test was used to compare proportions 
and analyse the degree of association between drug effi-
cacy and haemoglobin genotype (AA or AS). Quantita-
tive variables were compared by the analysis of variance. 
The 95  % confidence interval (95  % CI) of percentages 
was calculated using the exact binomial test. The level of 
significance (P) was fixed at 0.05 for all statistical tests.
Ethical approval
The present study was reviewed and approved by the 
institutional ethics committee of research in health sci-
ence (CERSSA) of the Congolese Ministry of Research 
and the Ministry of Health and Population of RoC. The 
study was conducted in accordance with the ethical 
principles of the Declaration of Helsinki. The commu-
nity was informed through meetings with community 
leaders, posters, and banners. Before children were 
recruited in the cohort, parents were informed about the 
objectives of the project, benefits, and constraints asso-
ciated with participation in the study. Parents or guard-
ians who agreed to participate in the study signed the 




From April 2010 to March 2011, 282 malaria episodes 
were registered during passive follow-up. Of these epi-
sodes, 262 were included in drug efficacy study: 129 were 
randomized to ASAQ group, while 133 were assigned 
to AL group (Fig.  2). Twenty children with malaria epi-
sode had extreme fatigue and/or repeated vomiting and 
were not included in the treatment protocol. They were 
referred to physicians in the paediatric ward of the dis-
trict hospital of Makélékélé for treatment with parenteral 
artesunate.
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In the ASAQ treatment group, 52 (40.3  %) children 
were under 5  years of age, while in the AL group 54 
(40.6 %) were under 5 years of age. Thirty-three patients 
with parasite density >200,000 asexual parasites/µL, but 
without danger signs of severe and complicated malaria, 
were included [15 (8 under 5 years of age) in the ASAQ 
group and 18 (8 under 5 years of age) in the AL group].
There were 112 (86.8 %) and 109 (82.0 %) AA haemo-
globin genotype in ASAQ and AL treatment groups, 
respectively (P  =  0.6). There were 17 of 129 (13.2  %) 
children and 24 of 133 (18.0  %) children with AS in 
the ASAQ and AL groups, respectively. The baseline 
characteristics of enrolled patients in each group were 
similar, with the exception of the mean geometric para-
site density (P < 0.001) (Table 1). Among ASAQ and AL 
groups, 23 (17.8 %) and 15 (12.7 %) patients were lost to 
follow-up on or before day 28, despite home visits.
Treatment outcomes
Cure rates on day 28
The PCR-uncorrected cure rates were 90.6 and 89.8 % in 
ASAQ and AL groups. Taking into account haemoglo-
bin genotype, the cure rates in AA carriers treated with 
ASAQ or AL were 90.0 and 88.6 %, respectively, while in 
Fig. 2 Enrolment and follow‑up profile
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AS patients, the cure rates for ASAQ and AL were 93.8 
and 90.9 %, respectively (Table 2). After PCR adjustment, 
the overall cure rates in ASAQ- and AL-treated chil-
dren were 97.0 and 96.4 %, respectively. In AA children, 
the cure rates for ASAQ and AL were 96.4 and 96.7  %, 
respectively, while in AS carriers treated with ASAQ and 
AL, the cure rates were 100 and 95.2 %, respectively.
Among children under 5  years of age, the PCR-cor-
rected cure rate was 97.3  % in the ASAQ group and 
95.2 % in the AL group. High parasitaemia did not influ-
ence the efficacy outcomes. Among 15 ASAQ-treated 
and 18 AL-treated children with day 0 parasite density 
more than 200,000 asexual parasites/µL, one recrudes-
cence was recorded in each group treatment, while in 
patients with 1000–200,000 asexual parasites/µL, two 
and three recrudescent infections were observed in 
ASAQ and AL groups, respectively.
In the ASAQ treatment group, 78/129 (60.5  %) chil-
dren received this drug during their first malaria epi-
sode, 51/129 (39.5 %) during their second, third or fourth 
malaria episodes (Table 3). Considering the first episode 
treated with ASAQ, 59/60 (98.3 %) had therapeutic suc-
cess and 1/60 (1.7  %) had treatment failure. There were 
three new infections and 15 patients lost to follow-up. 
Of 51 patients previously treated with AL during the first 
Table 1 Basic clinical and  parasitological characteristics 
of patients in the cohort with malarial episodes
Anaemia was defined as haemoglobin (Hb) <11 g/dL
GMPD geometric mean parasite density, PD parasite density
ASAQ AL P
Number of patients 129 133
Age (months), mean (±SD) 64.9 ± 33.0 65.0 ± 30.6 1
Sex: female/male 42/70 57/76 0.09
Weight (kg), mean (±SD) 19.8 ± 6.3 19.6 ± 5.6 0.8
Axillary temperature (°C), mean 
(±SD)
38.0 ± 1.0 37.6 ± 1.3 0.5
GMPD, asexual parasites/µL 29,100 30,700 0.5
 Range 950–388,000 800–725,000
 PD <1000, N (%) 4 (3.1) 3 (2.3) 1
 PD 1000–200,000, N (%) 110 (85.3) 112 (84.2) 0.7
 PD ≥200,000, N (%) 15 (11.6) 18 (13.5) 0.5
Mean haemoglobin, g/dL (±SD) 10.6 (1.1) 10.5 (1.3) 0.5
 Anaemia (Hb < 11 g/dL), N (%) 75 (58.1 %) 78 (58.6) 0.9
AA genotype, N (%) 112 (86.8) 109 (82.0) 0.4
 GMPD, asexual parasites/µL 29,500 30,300 0.8
 Range 950–376,000 800–725,000
AS genotype, N (%) 17 (13.2) 24 (18.0) 0.3
 GMPD, asexual parasites/µL 19,000 39,300 0.0001
 Range 950–388,000 3360–487,000
Table 2 Treatment outcomes of ASAQ and AL treatment, per-protocol analysis
ASAQ artesunate-amodiaquine, AL artemether-lumefantrine, ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical 
and parasitological response
ASAQ AL
Overall AA AS Overall AA AS
Number of patients, N 129 112 17 133 109 24
PCR uncorrected responses on day 28
 Lost to follow‑up, N (%) 22 (17.1) 22 (19.6) 1 (5.9) 15 (11.3) 13 (11.9) 2 (8.3)
 Eligible, N (%) 107 (82.9) 90 (80.4) 16 (94.1) 118 (88.7) 96 (88.1) 22 (91.7)
 Failure, N (%) 10 (9.4) 9 (10.0) 1 (6.2) 12 (10.2) 10 (10.4) 2 (9.1)
 ETF, N (%) 0 0 0 0 0 0
 LCF, N (%) 5 (4.7) 4 (4.4) 1 (6.2) 5 (4.2) 5 (5.2) 0
 LPF, N (%) 5 (4.7) 5 (5.6) 0 7 (5.9) 5 (5.2) 2 (9.1)
 ACPR, N (%) 97 (90.6) 81 (90.0) 15 (93.8) 106 (89.8) 86 (89.6) 20 (90.9)
PCR corrected responses on day 28
 Loss of follow up + new infection, N (%) 30 (23.3) 28 (25.0) 2 (11.8) 23 (17.3) 20 (18.3) 3 (12.5)
 Eligible, N (%) 99 (76.7) 84 (75.0) 15 (88.2) 110 (82.7) 89 (81.7) 21 (87.5)
 Failure, N (%) 3 (3.0) 3 (3.6) 0 4 (3.6) 3 (3.3) 1 (4.8)
 ETF, N (%) 0 0 0 0 0 0
 ACPR, N (%) 96 (97.0) 81 (96.4) 15 (100) 106 (96.4) 86 (96.6) 20 (95.2)
 Recrudescence, N 3 3 0 4 3 1
 New infection, N 7 6 1 8 7 1
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episode, 37/39 (94.9 %) and 2/39 (5.1 %) responded with 
treatment success and treatment failure, respectively. In 
this group, five new infections and seven lost to follow-
up were registered.
In the AL treatment group, 87/133 (65.4  %) received 
this drug during the first malaria episode, of which 69 
(94.5  %) were successfully treated (ACPR), four (5.5  %) 
failures, four new infections, and 10 lost-to-follow-up 
(Table 3). Of 46 patients (34.6 %) who had been treated 
previously with ASAQ during their first episode, 37/37 
(100  %) were therapeutic success, four were new infec-
tions, and five were lost to follow-up.
Fever and parasites clearance from day 0 to day 3
Among patients assigned to ASAQ treatment group, 
94, 98 and 97  % became afebrile on day 1, 2, and 3, 
respectively. Among patients in AL group, 91, 96, and 
97 % were afebrile on day 1, 2, and 3, respectively. On day 
2 and day 3, the number of patients with positive smears 
and parasitaemia decreased considerably. In the ASAQ 
treatment group, 5 of 130 patients (3.8 %) still had posi-
tive smears on day 2, with a geometric mean of 87 asex-
ual parasites/µL. On day 3, none of the patients followed 
(n = 121) had a positive smear.
Treatment safety
Between day 0 and day 7, a total of 166 and 111 adverse 
events were reported by patients treated with ASAQ and 
AL, respectively (Table  4). Asthenia was the most com-
monly reported adverse event and was more frequent 
in the ASAQ group (P =  0.02). This side effect was fol-
lowed by vomiting, abdominal pain, diarrhoea, headache, 
Table 3 Efficacy of ASAQ and AL as first-line and second-line treatments
ASAQ artesunate-amodiaquine, AL artemether-lumefantrine, ACPR adequate clinical and parasitological response
First treated malaria episode ≥Second treated malaria episode
ASAQ
 ACPR, N (%) 59 (98.3) 37 (94.9) RR = 1.04 (0.96–1.12)
 Recrudescence, N (%) 1 (1.7) 2 (5.1) P = 0.3
 New infection 3 5
 Lost‑to‑follow‑up 15 7
AL
 ACPR, N (%) 69 (94.5) 37 (100.0) RR = 0.95 (0.89–1.00)
 Recrudescence, N (%) 4 (5.5) 0 P = 0.19
 New infection 4 4
 Lost‑to‑follow‑up 10 5
RR = 1.04 (0.98–1.11), P = 0.2 RR = 0.95 (0.88–1.02), P = 0.26
Table 4 Clinical adverse events in the per protocol population
ASAQ artesunate-amodiaquine, AL artemether-lumefantrine
ASAQ (number of patients) AL (number of patients) P
D0 D1 D2 D3 D7 Total % D0 D1 D2 D3 D7 Total %
Adverse effects 129 125 123 119 114 – 133 132 130 125 126 –
Fatigue 2 18 19 25 1 65 10.7 3 14 12 5 4 38 5.9 0.02
Anorexia 3 1 1 2 2 9 1.5 0 1 1 2 1 5 0.8 0.2
Vomiting 8 10 4 4 2 28 4.6 11 9 5 0 1 26 4.0 0.6
Abdominal pain 3 6 4 4 2 19 3.1 2 2 2 3 5 14 2.2 0.3
Diarrhoea 2 3 4 0 2 11 1.8 9 2 1 0 0 12 1.9 0.9
Nausea 0 3 1 2 0 6 1 0 0 1 0 1 2 0.3 0.2
Headache 3 3 1 0 2 9 1.5 0 2 2 2 2 8 1.2 0.7
Jaundice 0 1 0 2 4 7 1.1 1 0 0 1 1 3 0.5 0.3
Dizziness 0 1 3 3 0 7 1.1 0 0 1 1 0 2 0.3 0.1
Pruritus 0 0 2 1 1 4 0.7 0 0 1 0 0 1 0.2 0.3
Rashes 0 0 0 0 1 1 0.2 0 0 0 0 0 0 0 –
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jaundice, and dizziness, with similar frequencies. Pruri-
tus occurred in four ASAQ treated children, while only 
one AL treated child reported pruritus. Rashes appeared 
in one ASAQ treated child.
Dizziness, nausea, headache and jaundice were 
reported more frequently (P  <  0.05) in children aged 
5–10 years in both ASAQ and AL treatment groups. Skin 
manifestations (rash, pruritus) were mostly observed in 
under-five children in both treatment groups. The differ-
ence in the frequency of fatigue, vomiting, and abdomi-
nal pain was not significantly different (P > 0.05) between 
the age groups <5 years and 5–10 years old.
Discussion
This is the second study on ASAQ and AL efficacy and 
safety in Brazzaville, the capital city of RoC. Under 
10 years children of the cohort with uncomplicated falci-
parum malaria were randomly treated with ASAQ or AL. 
The presence of sickle cells was determined to assess if 
they influence ACT efficacy in children.
All children recruited in the cohort reside in the subur-
ban area in the south of Brazzaville. Despite the impact of 
urbanization, malaria transmission is still intense in this 
area where children who are frequently infected with high 
parasite loads without signs of severe malaria are usually 
treated in health facilities for uncomplicated malaria. In 
the present cohort, high parasitaemias (>200,000 asexual 
parasites/µL) were similarly distributed in under-five 
children and those between 5 and 10 years old.
Data of this randomized study confirm the high and 
comparable efficacy of these two forms of ACT in Braz-
zaville, confirming previous non-randomized trials 
conducted from 2005 to 2006 [17, 18]. Data were com-
pared based on per protocol analysis. As in the previous 
studies, ASAQ treatment was fully supervised, but AL 
administration was partially supervised, as in many other 
studies conducted in Africa. While ASAQ was non-co-
formulated combination in the study conducted in 2005–
2006, patients received the standard dose (quarter, half, 
or three-quarters of amodiaquine and artesunate tablets) 
according to their body weight [18]. In the present study, 
co-formulated ASAQ was administered according to 
manufacturer’s instructions. The PCR-corrected ASAQ 
efficacy in the previous study was 94.4  % among 151 
patients while in the present study the efficacy was 97.0 % 
(n =  97 patients, p =  0.6). The PCR-corrected AL effi-
cacy was 97.1 % in 67 patients in the previous study [17]. 
By comparison, AL efficacy was 96.4  % in 106 patients 
included in the present study (p = 0.9).
Treatment was systematically switched after a pre-
vious uncomplicated malaria episode: the patient was 
treated with AL if he or she had been previously treated 
with ASAQ, and the patient was treated with ASAQ, if 
the previous treatment had been AL. Both combinations 
for the first- and second-line malaria management had a 
comparable efficacy. In accordance with the Congolese 
national policy, ASAQ treatment failures were treated 
with AL. These results suggest that in public health 
centres either ASAQ or AL can be used as the first-line 
drug and offer the possibility to use AL to treat patients 
who are reluctant to take ASAQ due to side effects or 
past history of allergic reactions. In the early 2000s, sub-
Saharan African countries started to implement the new 
anti-malarial drug policy based on ACT [11]. Among 43 
sub-Saharan countries, 15 adopted ASAQ, 22 AL, and 
2 both ASAQ and AL [30]. At that time, the availability 
of ACT was the main criterion of choice. Drug efficacy 
studies had not been carried out prior to the adoption of 
new policies in most countries. In 2014, RoC modified 
the national anti-malarial drug policy: AL for the first-
line treatment and ASAQ as the second-line drug. The 
main reason advanced by the National Malaria Control 
Programme was that ASAQ is associated with more side 
effects than AL [31]. However, there has been no phar-
macovigilance study or studies on the acceptability of 
ASAQ and AL.
In this study the percentage of patients with at least 
one side effect associated with ASAQ intake was higher 
than that of patients treated with AL. In particular, asthe-
nia was reported more frequently after ASAQ treatment. 
Previous studies have reported that patients receiving AQ 
monotherapy or AQ in combination with another anti-
malarial drug complained of fatigue, abdominal pain, 
and vomiting [32, 33]. In Democratic Republic of Congo 
(DR Congo), anorexia and physical weakness were more 
commonly observed after ASAQ treatment, as compared 
with AL [34]. In recent years, pharmacies in Congo offer 
a wide range of AL specialties, including specialties for 
adults and dispersible formulations for young children. 
Pharmaceutical firms are also promoting AL special-
ties. These factors are expected to favour a pronounced 
increase in the use of and reliance on AL to treat uncom-
plicated malaria in the country.
Sickle cell disease is the most common genetic 
disease in sub-Saharan African countries. It was 
estimated that in 2010 the world recorded 305,800 
newborns with sickle cell trait, with DR Congo 
(140,800) and Nigeria (91,000) being the most 
affected [35]. In Gabonese hospitals, 16.3 and 1.4  % 
of newborns were carriers of AS and SS genotypes, 
respectively; in the DR Congo, there were 17.6 and 
1.2 % of newborns with AS and SS genotypes, respec-
tively [36]. Sickle cell trait is, therefore, widely pre-
sent in African countries which carry much of 
malaria burden in the world [37]. The heterozygous 
genotype AS is also known to provide protection 
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against P. falciparum malaria [38–41]. It is, therefore, 
of interest to investigate the effect of sickle cell trait 
on ACT efficacy. For intermittent preventive treat-
ment of malaria in children, studies have shown that 
sulfadoxine-pyrimethamine (SP) is more effective 
than CQ in paediatric carriers of HbAS [42]. More-
over, when treated with SP, twice as many HbAA 
children had failure than those with HbAS [20]. The 
present study has shown that ASAQ and AL have a 
comparable efficacy in malaria-infected children with 
HbAA and HbAS.
Conclusion
This first randomized study in Brazzaville, conducted 
6  years after the change of policy against malaria and 
6  years after the first ASAQ and AL non-randomized 
studies, confirms the high efficacy of these combina-
tions, both of which are currently used in co-formulation 
whereas in 2006, only AL was co-formulated. ACT effi-
cacy in patients carrying AA and AS haemoglobin allows 
the use of these drugs regardless of sickle cell trait. The 
recurring problem of adverse events associated with 
ASAQ warrants further studies on the acceptability of 
both ACT.
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